Literature DB >> 16916960

Type I interferon production in HIV-infected patients.

Anne Hosmalin1, Pierre Lebon.   

Abstract

Type I IFNs display multiple biological effects. They have a strong antiviral action, not only directly but also indirectly through activation of the immune system. They may also have actions that are deleterious for the host. The cells that produce type I IFN are mostly plasmacytoid dendritic cells (pDC), but this depends on the viral stimulus. The migration and distribution of pDC into lymphoid organs, driven by chemokine interactions with their ligands, determines interaction with different cell types. In HIV infection, IFN production in vitro is impaired during primary infection and later in association with opportunistic infections. Circulating pDC numbers are decreased in parallel. These parameters may be used to help assess the prognosis of the disease and to monitor treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16916960     DOI: 10.1189/jlb.0306154

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  37 in total

1.  HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype.

Authors:  Simona Fiorentini; Elena Riboldi; Fabio Facchetti; Manuela Avolio; Marco Fabbri; Giorgio Tosti; Pablo D Becker; Carlos A Guzman; Silvano Sozzani; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-29       Impact factor: 11.205

2.  HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism.

Authors:  Olivier Manches; David Munn; Anahita Fallahi; Jeffrey Lifson; Laurence Chaperot; Joel Plumas; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 3.  Regulation of antiviral T cell responses by type I interferons.

Authors:  Josh Crouse; Ulrich Kalinke; Annette Oxenius
Journal:  Nat Rev Immunol       Date:  2015-03-20       Impact factor: 53.106

4.  Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.

Authors:  Michelle Wilkison; Katherine Gauss; Yanchao Ran; Steve Searles; David Taylor; Nicole Meissner
Journal:  Am J Pathol       Date:  2012-05-22       Impact factor: 4.307

Review 5.  Decoding the complexity of type I interferon to treat persistent viral infections.

Authors:  Elizabeth B Wilson; David G Brooks
Journal:  Trends Microbiol       Date:  2013-11-08       Impact factor: 17.079

6.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response.

Authors:  Béatrice Jacquelin; Véronique Mayau; Brice Targat; Anne-Sophie Liovat; Désirée Kunkel; Gaël Petitjean; Marie-Agnès Dillies; Pierre Roques; Cécile Butor; Guido Silvestri; Luis D Giavedoni; Pierre Lebon; Françoise Barré-Sinoussi; Arndt Benecke; Michaela C Müller-Trutwin
Journal:  J Clin Invest       Date:  2009-12       Impact factor: 14.808

7.  Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections.

Authors:  Elina I Zuniga; Li-Ying Liou; Lauren Mack; Marilyn Mendoza; Michael B A Oldstone
Journal:  Cell Host Microbe       Date:  2008-10-16       Impact factor: 21.023

8.  ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication.

Authors:  Guerline Clerzius; Jean-François Gélinas; Aïcha Daher; Marion Bonnet; Eliane F Meurs; Anne Gatignol
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

9.  KIR2DL4 copy number variation is associated with CD4+ T-cell depletion and function of cytokine-producing NK cell subsets in SIV-infected Mamu-A*01-negative rhesus macaques.

Authors:  Ina Hellmann; Norman L Letvin; Jörn E Schmitz
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

10.  Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.

Authors:  Daniela Vendrame; Marion Sourisseau; Virginie Perrin; Olivier Schwartz; Fabrizio Mammano
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.